PT1531831E - Formulacao de fosinopril - Google Patents

Formulacao de fosinopril

Info

Publication number
PT1531831E
PT1531831E PT03706893T PT03706893T PT1531831E PT 1531831 E PT1531831 E PT 1531831E PT 03706893 T PT03706893 T PT 03706893T PT 03706893 T PT03706893 T PT 03706893T PT 1531831 E PT1531831 E PT 1531831E
Authority
PT
Portugal
Prior art keywords
formulation
phosinopril
fosinopril
fosinoprilat
ace
Prior art date
Application number
PT03706893T
Other languages
English (en)
Inventor
Eyjolfsson Reynir
Original Assignee
Actavis Group Hf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36715398&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1531831(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actavis Group Hf filed Critical Actavis Group Hf
Publication of PT1531831E publication Critical patent/PT1531831E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT03706893T 2002-03-19 2003-03-19 Formulacao de fosinopril PT1531831E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IS6315A IS1935B (is) 2002-03-19 2002-03-19 Fósínópríl lyfjasamsetning

Publications (1)

Publication Number Publication Date
PT1531831E true PT1531831E (pt) 2006-05-31

Family

ID=36715398

Family Applications (1)

Application Number Title Priority Date Filing Date
PT03706893T PT1531831E (pt) 2002-03-19 2003-03-19 Formulacao de fosinopril

Country Status (13)

Country Link
US (1) US7045511B2 (pt)
EP (1) EP1531831B1 (pt)
AT (1) ATE314076T1 (pt)
AU (1) AU2003208599A1 (pt)
DE (1) DE60303041T2 (pt)
DK (1) DK1531831T3 (pt)
EA (1) EA008171B1 (pt)
ES (1) ES2256721T3 (pt)
IS (1) IS1935B (pt)
NO (1) NO20044390L (pt)
PT (1) PT1531831E (pt)
UA (1) UA78988C2 (pt)
WO (1) WO2003077929A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1635792T3 (da) * 2003-06-26 2009-06-15 Teva Pharma Stabile farmaceutiske sammensætninger af 2-aza-bicyklo-3.3.0-oktan-3-carboxylsyrederivater
US20050095287A1 (en) * 2003-10-29 2005-05-05 Matharu Amol S. Fosinopril composition
GB2411355B (en) 2004-02-27 2006-02-22 Niche Generics Ltd Pharmaceutical composition
AU2006213663A1 (en) * 2005-02-11 2006-08-17 Aventis Pharmaceuticals Inc. Substituted propane phosphinic acid esters
WO2006100602A2 (en) * 2005-03-22 2006-09-28 Aurobindo Pharma Ltd Immediate release stable solid oral dosage forms op fosinopril
CA2647705A1 (en) * 2006-04-19 2007-10-25 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivatives
GB0612540D0 (en) * 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
EP1889629B1 (en) * 2006-07-10 2008-08-27 Teva Pharmaceutical Industries Ltd Stable formulation comprising a combination of a moisture sensitive drug and a second drug and manufacturing procedure thereof
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4337201A (en) * 1980-12-04 1982-06-29 E. R. Squibb & Sons, Inc. Phosphinylalkanoyl substituted prolines
US5006344A (en) * 1989-07-10 1991-04-09 E. R. Squibb & Sons, Inc. Fosinopril tablet formulations
US6521647B2 (en) * 2000-04-04 2003-02-18 Pfizer Inc. Treatment of renal disorders
CA2330904C (en) * 2001-01-11 2006-10-24 Bernard Charles Sherman Fosinopril sodium tablet formulation
PL370599A1 (en) * 2001-11-02 2005-05-30 Pfizer Products Inc. Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
ITMI20012366A1 (it) * 2001-11-09 2003-05-09 Farmatron Ltd Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali

Also Published As

Publication number Publication date
NO20044390L (no) 2004-12-15
EA008171B1 (ru) 2007-04-27
EP1531831B1 (en) 2005-12-28
US20050256086A1 (en) 2005-11-17
DE60303041T2 (de) 2006-08-24
ES2256721T3 (es) 2006-07-16
UA78988C2 (en) 2007-05-10
EA200401218A1 (ru) 2005-12-29
ATE314076T1 (de) 2006-01-15
EP1531831A1 (en) 2005-05-25
WO2003077929A1 (en) 2003-09-25
IS1935B (is) 2004-06-16
DK1531831T3 (da) 2006-05-15
DE60303041D1 (de) 2006-02-02
AU2003208599A1 (en) 2003-09-29
IS6315A (is) 2003-09-20
US7045511B2 (en) 2006-05-16

Similar Documents

Publication Publication Date Title
HK1076605A1 (en) Formulations
CY1109457T1 (el) Παραγωγο aminoαλκοολης ή παραγωγο φωσφονικου οξεος και φαρμακευτικη συνθεση που τα περιεχει
MA29854B1 (fr) Nouvelle formulation
TW200621313A (en) Pharmaceutical compositions
MXPA04004464A (es) Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades.
MA29857B1 (fr) Derives de triazolopyridine en tant qu'inhibiteurs de lipases et phospholipases
BR0209431A (pt) Novos compostos de 4-anilinoquinolino-3-carboxamidas
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
MY138252A (en) Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease
ATE529430T1 (de) Caspase-hemmer-propharmaka
SG10201809390QA (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
MA29858B1 (fr) Derives de carbamoylbenzotriazole en tant qu'inhibiteurs de lipases et phospholipases
EA200601608A1 (ru) Способ производства твёрдой фармацевтической композиции
WO2008048801A3 (en) Phenylalkylamino carbamate compositions
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
MX2009003929A (es) Composiciones de fenilalquil carbamato.
MXPA04006266A (es) Pirimidotriazinas como inhibidores de fosfatasa.
PT1531831E (pt) Formulacao de fosinopril
BR0112245B1 (pt) Éster de ácido 4-alcóxi-ciclohexano-1-amino-carboxílico
NO20083183L (no) Fast farmasoytisk sammensetning inneholdende irbesartan
WO2008036316A3 (en) Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease
MXPA05013012A (es) Formulaciones blanqueadoras fluorescentes estables al almacenamiento.
MXPA06000636A (es) Formulaciones semi-solidas para la administracion oral de taxoides.
TW200640860A (en) Lercanidipine free base
WO2007026379A3 (en) Novel crystalline forms of risedronate monosodium